Introduction to Advanced cSCC Management

Managing advanced cutaneous squamous cell carcinoma (cSCC) remains a significant challenge for clinicians, especially when initial treatments fail. While the introduction of immunotherapy has significantly improved prognosis, many patients eventually develop resistance. Consequently, researchers are exploring anti-EGFR and anti-PD1 therapy as a potential salvage strategy for those with refractory disease. This approach aims to overcome the limitations of monotherapy by targeting multiple pathways simultaneously.

Study Design and Methodology

A retrospective, monocentric cohort study recently evaluated patients treated between 2013 and 2024. The study focused on individuals with advanced cSCC that had progressed despite anti-PD1 monotherapy. Most participants were male, with a median age of 63 years. Furthermore, many patients had previously received both immunotherapy and traditional chemotherapy combined with cetuximab. The primary treatment regimen involved cetuximab (500 mg/m2) combined with pembrolizumab every three weeks.

Key Findings: Efficacy and Response Rates

The results indicated that the combination treatment offers substantial clinical activity. The overall response rate (ORR) reached 38.5%, a notable figure in a heavily pretreated population. Specifically, 15.5% of patients achieved a complete and durable response even after treatment discontinuation. Moreover, 23% of patients exhibited partial responses. Most responses occurred early in the treatment course, with some patients showing deepening responses over several months. These findings suggest that the combination can effectively re-sensitize tumors to therapy.

Safety Profile of Anti-EGFR and Anti-PD1 Therapy

Patient safety is a critical consideration in later-line strategies. In this study, the safety profile was generally acceptable. Most adverse events were categorized as grade 1. Notably, only two cases experienced grade 3 toxicity, which presented as an acneiform rash typically associated with EGFR inhibitors. Because the side effects were manageable, the combination remains a viable option for patients who may be frail or have limited alternative treatment lines.

Clinical Implications

This study supports the use of combined targeting in a real-life clinical setting. By integrating different mechanisms of action, clinicians can potentially extend survival in refractory cases. Additionally, the early onset of response allows for rapid assessment of treatment benefit. Future prospective trials will likely further refine the optimal sequencing of these agents.

Frequently Asked Questions

What is the typical response rate for this combination in refractory cSCC?

In patients who have already failed anti-PD1 monotherapy, the combination of anti-EGFR and anti-PD1 therapy showed an overall response rate of approximately 38.5%.

What are the common side effects of this treatment?

Most side effects are mild, predominantly grade 1. The most common higher-grade toxicity is an acneiform rash, which is a known side effect of cetuximab.

Who is eligible for this later-line therapy?

This strategy is typically reserved for patients with advanced or metastatic cSCC who have progressed on standard anti-PD1 inhibitors and have few other systemic treatment options.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Guy C et al. Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study. Oncologist. 2026 Mar 13. doi: undefined. PMID: 41830427.

Stratigos AJ, et al. European consensus-based interdisciplinary guideline for the diagnosis and treatment of cutaneous squamous cell carcinoma. Eur J Cancer. 2020;131:22-59.

Migden MR, et al. Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:1410-1422.